Kamada (KMDA) Current Leases (2018 - 2026)
Kamada's (KMDA) quarterly Current Leases came in at $2.3 million in Q2 2026, up 22.51% on a YoY basis from $1.9 million in Q2 2025, and up 4.0% quarter-over-quarter from $2.2 million in Q1 2026.
Analysis
Kamada (KMDA) Current Leases (2018 - 2026) Analysis & Trends
Kamada (KMDA) has reported Current Leases for 9 consecutive years, with $2.3 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Current Leases rose 22.51% year-over-year to $2.3 million; the trailing twelve-month figure through Jun 2026 stood at $2.3 million (up 22.51% YoY), and the FY2025 full-year result was $2.1 million, up 30.04% from the prior year.
- Current Leases improved to $2.3 million in Q2 2026 per KMDA's latest filing, from $2.2 million in the prior quarter.
- Across five years, Current Leases topped out at $2.3 million in Q2 2026 and bottomed at $1.0 million in Q3 2022.
- Historically, Current Leases has averaged $1.5 million across 5 years, with a median of $1.5 million in 2024.
- The sharpest annual moves came in 2022 and 2023: Current Leases decreased 14.99% in 2022, then surged 41.4% in 2023.
- Over 5 years, Current Leases stood at $1.0 million in 2022, then soared by 36.22% to $1.4 million in 2023, then gained by 17.85% to $1.6 million in 2024, then soared by 30.04% to $2.1 million in 2025, then grew by 7.78% to $2.3 million in 2026.
- According to Business Quant data, Current Leases over the past three periods registered $2.3 million, $2.2 million, and $2.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 720.00 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 11.00 Mn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 45.93 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 12.38 Mn |
| 10 | Kamada | 473.57 Mn | 403.43 Mn | 22.47 Mn | 2.29 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.29 Mn |
| Mar 31, 2026 | 2.20 Mn |
| Dec 31, 2025 | 2.12 Mn |
| Sep 30, 2025 | 1.91 Mn |
| Jun 30, 2025 | 1.87 Mn |
| Mar 31, 2025 | 1.78 Mn |
| Dec 31, 2024 | 1.63 Mn |
| Sep 30, 2024 | 1.59 Mn |
| Jun 30, 2024 | 1.49 Mn |
| Mar 31, 2024 | 1.47 Mn |
| Dec 31, 2023 | 1.38 Mn |
| Sep 30, 2023 | 1.14 Mn |
| Jun 30, 2023 | 1.06 Mn |
| Mar 31, 2023 | 1.44 Mn |
| Dec 31, 2022 | 1.02 Mn |
| Sep 30, 2022 | 1.00 Mn |
| Jun 30, 2022 | 1.01 Mn |
| Mar 31, 2022 | 1.02 Mn |
| Dec 31, 2021 | 1.15 Mn |
| Sep 30, 2021 | 1.18 Mn |